Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care.
All 324 patients admitted over sixteen months to a general intensive therapy unit (ITU) were prospectively studied to assess the effect of a novel prophylactic antibiotic regimen on the incidence of acquired infection. Consecutive control (161 patients) and test (163 patients) groups were analyzed. In the control group, antibiotic administration was determined by clinical and microbiological evidence of infection. In the test group, treatment consisted of a triple regimen of selective decontamination of the digestive tract (polymyxin E, tobramycin, and amphotericin B) administered throughout the ITU stay, systemic cefotaxime administered for the initial four days, and regular microbiological screening of multiple sites. The test group showed a striking and consistent reduction in colonisation of the digestive tract with aerobic gram-negative bacilli, and there was a substantial reduction in the incidence of acquired infection (24% to 10%). Mortality in certain categories of patients was also reduced. There is now a considerable body of evidence to justify the more widespread use of this selective parenteral and enteral anti-sepsis regimen (SPEAR) in general intensive care practice.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002439:Cefotaxime / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000517:prevention & control*; D004064:Digestive System / Q000382:microbiology*; D004203:Disinfection / Q000379:methods*; D004338:Drug Combinations; D006801:Humans; D007362:Intensive Care Units; D007902:Length of Stay; D008875:Middle Aged; D011183:Postoperative Complications / Q000382:microbiology / Q000517:prevention & control; D011446:Prospective Studies; D011549:Pseudomonas / Q000187:drug effects / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000517:prevention & control*; D012140:Respiratory Tract Diseases / Q000382:microbiology / Q000517:prevention & control; D013242:Sterilization / Q000379:methods*; D015003:Yeasts / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D002439:Cefotaxime